RAPP RAPPORT THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, RAPPORT THERAPEUTICS INC reported revenue of $0, net income of −$56.6M and diluted EPS of −$1.19; for the fiscal year ended December 2025 revenue was n/a.
RAPP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$125M, net income −$111M (margin n/a), EPS −$2.86
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$83.1M, net income −$78.3M (margin n/a), EPS −$3.78
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$36.2M, net income −$34.8M (margin n/a), EPS −$23.10
RAPP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$56.6M, EPS −$1.19
- Quarter ended Mar 31, 2026: revenue $20.0M, net income −$19.9M, EPS −$0.42
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$33.8M, EPS −$0.72
- Quarter ended Sep 30, 2025: revenue n/a, net income −$26.9M, EPS −$0.71
- Quarter ended Jun 30, 2025: revenue $0, net income −$26.7M, EPS −$0.75
- Quarter ended Mar 31, 2025: revenue $0, net income −$24.1M, EPS −$0.68
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$20.0M, EPS $9.49
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.5M, EPS −$0.50
- Quarter ended Jun 30, 2024: revenue n/a, net income −$18.1M, EPS −$1.70
- Quarter ended Mar 31, 2024: revenue n/a, net income −$22.7M, EPS −$11.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$13.5M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$8.71M, EPS −$5.70
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.41M, EPS −$4.45
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.15M, EPS n/a
RAPP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$87.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$64.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$27.2M, share buybacks n/a
RAPP balance sheet
- Jun 30, 2026: cash $63.6M, total assets $459M, total liabilities $36.1M, shareholders' equity $423M
- Mar 31, 2026: cash $78.1M, total assets $498M, total liabilities $26.1M, shareholders' equity $472M
- Dec 31, 2025: cash $52.6M, total assets $512M, total liabilities $27.8M, shareholders' equity $485M
- Sep 30, 2025: cash $251M, total assets $535M, total liabilities $23.7M, shareholders' equity $512M
- Jun 30, 2025: cash $55.1M, total assets $285M, total liabilities $22.0M, shareholders' equity $264M
- Mar 31, 2025: cash $57.6M, total assets $302M, total liabilities $16.2M, shareholders' equity $286M
- Dec 31, 2024: cash $56.8M, total assets $315M, total liabilities $9.51M, shareholders' equity $305M
- Sep 30, 2024: cash $39.3M, total assets $331M, total liabilities $8.03M, shareholders' equity $323M
Is RAPP profitable?
No. RAPPORT THERAPEUTICS INC lost $137M over the last four quarters.
What is RAPP's EPS?
Diluted earnings per share over the last four quarters were −$3.04; −$1.19 in the latest quarter.